InsidersTradesSigma
Ardelyx, INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Ardelyx, INC. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Ardelyx, INC. has recorded 383 reports. Market capitalisation: €1.3bn. The latest transaction was reported on 22 June 2026 (Levée d'options). Among the most active insiders: RAAB MICHAEL. The full history is openly available.
383
Insider Decl.
0
Thresholds
€6m
44 ops.
Buy Volume
€10m
225 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ardelyx, INC. Strong Buy (bullish), based on 10 analysts. Average price target: US$16.30.
52Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,607 of 25,899 companies
30.9
score / 100
Value24
Quality38
FCF yld-3.3%
Earn yld-4.6%
EV/EBITDA·
ROE-39%
Gross mgn90%
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 June 2026
Declarations383 total
31,000 sharesCommon StockSEC:0001869194-26-000008:0
81,898 sharesCommon StockSEC:0001869194-26-000008:1
20,282 sharesCommon StockSEC:0001219871-26-000003:0
26,455 sharesCommon StockSEC:0001219871-26-000003:1
12,345 sharesCommon StockSEC:0001291937-26-000003:0
26,455 sharesCommon StockSEC:0001291937-26-000003:1
26,455 sharesCommon StockSEC:0001313397-26-000002:0
26,455 sharesCommon StockSEC:0001620152-26-000005:0
26,455 sharesCommon StockSEC:0001792150-26-000002:0
26,455 sharesCommon StockSEC:0001846905-26-000004:0
26,455 sharesCommon StockSEC:0001799355-26-000006:0
20,833 sharesCommon StockSEC:0001321402-26-000014:0
41,666 sharesCommon StockSEC:0001321402-26-000014:1
1,036 shares@ US$6.26750.0004% mcap7.6% of flowCommon StockSEC:0002044416-26-000005:1
1,846 shares@ US$6.26750.0007% mcap100.0% of flowCommon StockSEC:0002088887-26-000004:0
1,455 shares@ US$6.26750.0006% mcap100.0% of flowCommon StockSEC:0002093095-26-000004:0
2,683 shares@ US$6.26750.0010% mcap19.7% of flowCommon StockSEC:0002044416-26-000005:0
2,306 shares@ US$6.26750.0009% mcap100.0% of flowCommon StockSEC:0001308911-26-000004:0
14,933 shares@ US$6.26750.0057% mcap2.5% of flowCommon StockSEC:0001321402-26-000012:0
7,861 shares@ US$6.26750.0030% mcap1.3% of flowCommon StockSEC:0001321402-26-000012:1
17,926 shares@ US$6.26750.0068% mcap3.1% of flowCommon StockSEC:0001321402-26-000012:2
14,028 shares@ US$6.26750.0053% mcap2.4% of flowCommon StockSEC:0001321402-26-000012:3
1,503 shares@ US$6.26750.0006% mcap0.8% of flowCommon StockSEC:0001869194-26-000006:0
2,157 shares@ US$6.26750.0008% mcap1.1% of flowCommon StockSEC:0001869194-26-000006:1
1,911 shares@ US$6.26750.0007% mcap1.0% of flowCommon StockSEC:0001869194-26-000006:2
25 of 383 declarations
About Ardelyx, INC.
Ardelyx, Inc. (ticker: ARDX) is a U.S.-listed biopharmaceutical company traded on the Nasdaq market in the United States. Headquartered in Waltham, Massachusetts, it was founded in October 2007 as Nteryx and later renamed Ardelyx in June 2008. The company’s core business is the discovery, development, and commercialization of innovative medicines aimed at significant unmet medical needs. From an equity research perspective, Ardelyx should be viewed as a commercial-stage biotech rather than a pure development-stage platform, because it already generates product revenue and is executing a direct commercialization strategy in the U.S. Ardelyx’s business model is centered on two approved products in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is marketed for adults with irritable bowel syndrome with constipation (IBS-C), while XPHOZAH is used in the treatment of hyperphosphatemia in adults with chronic kidney disease on dialysis. Both products are based on tenapanor and reflect Ardelyx’s differentiated scientific platform, which targets NHE3 inhibition. This gives the company a focused therapeutic profile spanning gastroenterology and nephrology, with a clinically distinct mechanism that supports its positioning versus broader-capability large-cap pharmaceutical peers. In competitive terms, Ardelyx remains a relatively specialized mid-cap player in a market dominated by larger pharmaceutical and biotech companies with deeper sales infrastructure and more diversified portfolios. Its key competitive strengths are the first-in-class nature of its assets, the commercial momentum of IBSRELA, and the continued market adoption of XPHOZAH. The company’s revenue base is currently concentrated in the United States, which makes its growth profile highly dependent on domestic commercialization execution, payer access, physician uptake, and ongoing product differentiation. Recent developments have reinforced the company’s growth narrative. Ardelyx reported strong commercial progress in 2025, including continued IBSRELA growth and increasing XPHOZAH adoption. In early 2026, management updated the strategic outlook and highlighted a new Phase 3 program for IBSRELA in chronic idiopathic constipation, as well as work on a next-generation NHE3 inhibitor, RDX10531. The company also made leadership changes during 2025, signaling an emphasis on execution, pipeline expansion, and long-term operational discipline. For investors following Nasdaq-listed healthcare names, Ardelyx offers a combination of commercial-stage revenue growth, pipeline optionality, and therapeutic specialization within the United States biopharma landscape.
